Cross-protective HCoV immunity reduces symptom development during SARS-CoV-2 infection.
Abela IA, Schwarzmüller M, Ulyte A, Radtke T, Haile SR, Ammann P, Raineri A, Rueegg S, Epp S, Berger C, Böni J, Manrique A, Audigé A, Huber M, Schreiber PW, Scheier T, Fehr J, Weber J, Rusert P, Günthard HF, Kouyos RD, Puhan MA, Kriemler S, Trkola A, Pasin C.
Abela IA, et al.
mBio. 2024 Feb 14;15(2):e0272223. doi: 10.1128/mbio.02722-23. Epub 2024 Jan 25.
mBio. 2024.
PMID: 38270455
Free PMC article.